Psilocybin in Cancer and Palliative Care: Distress, Meaning and Choice

Andrew T. Austin · 11 October 2026

The clinical priority for psilocybin in cancer care is relief of suffering while preserving the person’s agency. A life-threatening diagnosis can alter the meaning of ordinary plans, relationships and the future. For some people, anxiety or depression becomes disabling; for others, the central difficulty is loss of meaning, dignity or a sense of belonging. Those experiences deserve attentive care without being reduced to a demand that the patient become more accepting.

Psilocybin-assisted therapy has produced substantial improvements in anxiety and depressive symptoms in small controlled trials involving people with cancer. These findings justify careful clinical interest. They do not establish that everyone with advanced illness should receive a psychedelic, that distress always requires drug treatment, or that psilocybin treats the cancer itself.¹²

On this page

• Cancer-related distress is not one diagnosis
• Palliative care can begin long before the final days
• What the controlled trials show
• How durable might relief be?
• Meaning, fear and the subjective experience
• Clinical suitability in serious illness
• Can lower-dose treatment reduce the burden?
• Care without pressure to transform
• The place of psilocybin in compassionate cancer care

Cancer-related distress is not one diagnosis

Psychological distress exists on a continuum. Understandable fear during investigation or treatment is different from a sustained depressive episode, a disabling anxiety disorder or an adjustment disorder. Demoralisation emphasises helplessness and loss of meaning; it can overlap with depression without being identical to it. A symptom score can help identify difficulty, but cannot replace a conversation about what the person is experiencing and what support they want.³

Emotional distress must also be distinguished from delirium. New or fluctuating confusion, impaired attention and changes in awareness can arise from medication, dehydration or illness. A quiet, withdrawn person may have hypoactive delirium rather than simply be depressed. These changes require medical assessment; interpreting them as an existential crisis risks delaying appropriate care.⁴

Assessment should make room for physical discomfort, isolation, uncertainty about treatment and concern for relatives. Interest in a novel psychological intervention should not displace attention to unresolved practical needs. Relief of pain, clear information, help with care arrangements and a trustworthy clinical relationship may be the most urgent intervention. Psilocybin, if considered, must fit within that wider understanding of suffering.

Palliative care can begin long before the final days

Palliative care addresses quality of life and physical, psychological, social and spiritual needs during serious illness. It can be provided alongside treatment intended to control or cure cancer. It is not synonymous with imminent death or the withdrawal of active medical care. This distinction is essential when considering psychedelic treatment, because studies of people with life-threatening cancer should not automatically be described as studies of people in their last days of life.⁵

Someone living for years with cancer may have time and energy for preparation, a prolonged medication session and continuing psychological work. Someone deteriorating quickly may find that same programme burdensome or impractical. The burden of treatment needs to be assessed alongside its possible benefit. A more intensive intervention is not necessarily more appropriate.

What the controlled trials show

Two trials published in 2016 provide important evidence. At Johns Hopkins, 51 people with life-threatening cancer diagnoses and symptoms of depression or anxiety received a high dose and a very low dose of psilocybin in a randomised crossover design, with psychological support. The higher dose produced substantially greater early improvements in mood and anxiety. Many participants continued to report benefit at six months.¹

At New York University, 29 people with cancer-related anxiety and depression received psilocybin or niacin, with psychotherapy, before crossing to the other condition. Before crossover, psilocybin produced greater reductions in anxiety and depression, alongside improvements in several measures of existential distress and quality of life. Benefits were still reported at later follow-up.²

The early controlled differences provide stronger evidence about causation than the later follow-up alone. Once both groups have received psilocybin, there is no longer a continuing untreated comparison. Persistent improvement remains clinically interesting, but its precise cause cannot be isolated in the same way. The samples were also small and selected, and the conspicuous drug effects make successful blinding difficult.

These treatments involved preparation, support during the altered state and follow-up. Their results cannot be transferred directly to taking mushrooms alone, attending an unregulated retreat or receiving a superficially similar service without comparable clinical safeguards. The studied intervention was a package of care.

How durable might relief be?

Long-term improvement is possible, but the available follow-up requires a careful reading. A later assessment contacted the surviving participants from the New York trial: 15 agreed to follow-up at an average of 3.2 years, with further assessment around 4.5 years. Sustained benefits were reported. However, this was a small survivor group without a long-term control condition. It cannot show that every original participant obtained lasting relief or that all later improvement was caused by the original treatment.⁶

A separate programme in a community cancer setting treated 30 people with cancer and major depressive disorder, using individual support and a group-based therapeutic framework. Depression improved over the initial eight weeks, but the study was open-label and did not include a randomised comparator.⁷ At two years, the follow-up reported sustained depression improvement in 14 of 28 participants. Some had received antidepressants or further psychedelic treatment in the intervening period. These outcomes cannot therefore be attributed to one dose acting alone for two years.⁸

Durability also means more than the persistence of a low questionnaire score. A patient may value a period of restored connection with family even if symptoms later return. Another may find a short improvement disappointing because it is followed by renewed distress. The timing and limits of benefit should be described explicitly, allowing for different experiences and priorities.

Meaning, fear and the subjective experience

Psilocybin can alter the felt relationship between self, body, memory and surroundings. Some participants describe greater connection, a changed perspective on illness or less fear of death. Others experience anxiety, disorientation or emotionally difficult material. Psilocin’s action at serotonin receptors helps explain the altered state, but a receptor mechanism does not establish what a particular experience will mean to a particular person.⁹

Associations between experiences described as mystical and later improvement have been reported in cancer trials. Such an association does not establish that a mystical experience is necessary, that a stronger experience is always better, or that a therapist should encourage a specific belief system.¹² Clinical support should accommodate religious, spiritual, secular and uncertain interpretations alike.

A powerful experience does not establish factual claims about an afterlife, the cause of an illness or the intentions of relatives. The distinction between personal meaning and factual accuracy matters when a patient is especially vulnerable to suggestion. Support should help the person explore what was useful without requiring agreement with the practitioner’s explanation.¹⁰

Clinical suitability in serious illness

Suitability depends on more than the severity of distress. The person must be able to understand the proposed intervention, communicate preferences and tolerate the demands of the session. Psychiatric history, physical stability, medication, fatigue and the availability of follow-up all matter. A research sample selected for relative stability does not establish safety in people with every form of advanced cancer or organ impairment.¹¹¹²

Acute anxiety, nausea, headache and changes in blood pressure may be manageable in a controlled setting, but can have different implications for someone who is physically frail or already struggling with symptom burden. Safety planning should anticipate deterioration rather than assume that every distressing symptom is part of a therapeutically useful process.¹³

Medication decisions require coordination with the team treating the cancer and associated symptoms. Evidence about many psychedelic drug interactions remains limited. A medication that changes the subjective response may also be essential for pain, mood or another illness. Necessary treatment should not be withdrawn abruptly merely to intensify a psychedelic experience.¹⁴

Can lower-dose treatment reduce the burden?

Repeated low-dose treatment is being investigated partly because lengthy psychedelic sessions can be difficult to deliver in advanced illness. The 2026 PSYCHED-PAL study enrolled 20 people with advanced incurable illness and severe psychological distress. Seventeen began the intervention and 13 completed it; most had cancer. Several completers reported meaningful improvements. No serious adverse events were reported, although mild or moderate events occurred.¹⁵

This was an open-label, single-arm study. It provides a preliminary feasibility signal, not proof that low-dose psilocybin is an effective or generally safe palliative treatment. Participants who withdrew because of deterioration or poor response are particularly relevant when considering what the intervention can achieve in ordinary practice. An encouraging proportion among completers should not be mistaken for the probability of benefit for everyone who starts.¹⁵

Reducing treatment burden is a worthwhile clinical aim, but lower intensity does not remove the need for a comparison group or systematic monitoring. Evidence from supported higher-dose treatment cannot simply be used to fill the gaps in evidence for repeated low doses.

Care without pressure to transform

The promise of rapid relief can be compelling when time feels limited. That makes honest communication more important, not less. Consent requires an explanation that benefit is uncertain, that an experience may be difficult, and that declining treatment is a legitimate choice. The patient should not feel responsible for disappointing relatives or a practitioner who believes the treatment ought to produce peace.

Preparation should include discussion of boundaries, touch, confidentiality and who will be present. A person’s willingness to accept reassurance during an altered state must not be interpreted as unrestricted consent. Appropriate professional boundaries are central to safety in psychedelic research and should remain central wherever such care is considered.¹¹

Follow-up should allow for mixed outcomes: relief alongside grief, connection alongside anger, or no discernible benefit at all. Persistent distress deserves further assessment and support. It should not be redescribed as resistance to healing or a failure to “let go”.

The place of psilocybin in compassionate cancer care

Psilocybin-assisted therapy is a developing approach to selected forms of cancer-related psychological distress. The controlled findings are encouraging, while the evidence about broader eligibility, comparative effectiveness and long-term outcomes remains incomplete. Neither enthusiasm nor understandable caution should obscure those distinctions.

The cancer itself, its physical complications and its treatment require their own medical care. Psychological benefit must not be represented as tumour control or longer survival: the trials discussed here do not establish those effects. Any psychedelic intervention belongs within coordinated oncology, palliative and psychological care, with the person’s wishes guiding the balance between opportunity and burden.

A worthwhile outcome offers more relief, more choice or more capacity to spend time in a way that matters to the person. It does not require an expected attitude towards death.

References

1. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181-1197. doi:10.1177/0269881116675513.
2. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165-1180. doi:10.1177/0269881116675512.
3. National Cancer Institute. Adjustment to Cancer: Anxiety and Distress (PDQ®)–Health Professional Version. Supportive and Palliative Care Editorial Board; accessed 11 October 2026.
4. National Cancer Institute. Delirium: Cancer Treatment Side Effect. Accessed 11 October 2026.
5. National Cancer Institute. Palliative Care in Cancer. Accessed 11 October 2026.
6. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155–166. doi:10.1177/0269881119897615.
7. Agrawal M, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2024. doi:10.1002/cncr.35010.
8. Agrawal M, Roddy K, Jenkins B, et al. Long-term benefits of single-dose psilocybin in depressed patients with cancer. Cancer. 2025. doi:10.1002/cncr.35889.
9. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355. doi:10.1124/pr.115.011478.
10. McGovern HT, Grimmer HJ, Doss MK, et al. An Integrated theory of false insights and beliefs under psychedelics. Commun Psychol. 2024;2:69. doi:10.1038/s44271-024-00120-6.
11. Johnson MW, Richards WA, Griffiths RR. Human Hallucinogen Research: Guidelines for Safety. J Psychopharmacol. 2008;22:603–620. doi:10.1177/0269881108093587.
12. Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81:1225–1235. doi:10.1001/jamapsychiatry.2024.2546.
13. Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7:e245960. doi:10.1001/jamanetworkopen.2024.5960.
14. Halman A, et al. Drug–drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. 2024. doi:10.1177/02698811231211219.
15. Downar J, Lapenskie J, Anderson K, et al. PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. Palliat Med. 2026;40:514-523. doi:10.1177/02692163261416269.

General medical information. Decisions about treatment, medication changes and persistent symptoms require an individual assessment by an appropriately qualified clinician.